Search research articles
Contact Us
Filters
Showing results (161-170 of 196) with videos related to
Page
of 20
Sort By:
EJNMMI Research
|
March 17, 2025
Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphoma
Michael Beck, Viktoria Blumenberg, Veit L Bücklein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2016
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot, et al.
Cancer Immunology Research
|
February 10, 2021
The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages
Dimitrios Mougiakakos, Christian Bach, Martin Böttcher, et al.
Immunity
|
July 21, 2021
β<sub>2</sub>-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression
Daniel Hofbauer, Dimitrios Mougiakakos, Luca Broggini, et al.
Blood
|
June 5, 2014
Abnormally differentiated CD4+ or CD8+ T cells with phenotypic and genetic features of double negative T cells in human Fas deficiency
Anne Rensing-Ehl, Simon Völkl, Carsten Speckmann, et al.
The Lancet. Rheumatology
|
May 3, 2025
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study
Melanie Hagen, Fabian Müller, Andreas Wirsching, et al.
Leukemia
|
April 15, 2018
Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway
Leonhard Busch, Dimitrios Mougiakakos, Maike Büttner-Herold, et al.
Blood
|
May 13, 2025
Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment
Richard Pelzl, Giulia Benintende, Franziska Gsottberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma
Michael Crump, Sirpa Leppä, Luis Fayad, et al.
Blood
|
June 24, 2021
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma
Kai Rejeski, Ariel Perez, Pierre Sesques, et al.
Page
of 20
Search research articles
Search
Showing results (161-170 of 196) with videos related to
Sort By:
Page
of 20
EJNMMI Research
|
March 17, 2025
Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphoma
Michael Beck, Viktoria Blumenberg, Veit L Bücklein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2016
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot, et al.
Cancer Immunology Research
|
February 10, 2021
The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages
Dimitrios Mougiakakos, Christian Bach, Martin Böttcher, et al.
Immunity
|
July 21, 2021
β<sub>2</sub>-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression
Daniel Hofbauer, Dimitrios Mougiakakos, Luca Broggini, et al.
Blood
|
June 5, 2014
Abnormally differentiated CD4+ or CD8+ T cells with phenotypic and genetic features of double negative T cells in human Fas deficiency
Anne Rensing-Ehl, Simon Völkl, Carsten Speckmann, et al.
The Lancet. Rheumatology
|
May 3, 2025
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study
Melanie Hagen, Fabian Müller, Andreas Wirsching, et al.
Leukemia
|
April 15, 2018
Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway
Leonhard Busch, Dimitrios Mougiakakos, Maike Büttner-Herold, et al.
Blood
|
May 13, 2025
Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment
Richard Pelzl, Giulia Benintende, Franziska Gsottberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma
Michael Crump, Sirpa Leppä, Luis Fayad, et al.
Blood
|
June 24, 2021
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma
Kai Rejeski, Ariel Perez, Pierre Sesques, et al.
Page
of 20